TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Cytokines
Immunotherapy
Killer Cells, Natural
Lymphocyte Activation
T-Lymphocytes
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
accepted:
21
06
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
14
7
2022
Statut:
ppublish
Résumé
Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ TransCon IL-2 β/γ was designed to optimally address these drawbacks. To abolish IL-2Rα binding yet retain strong IL-2Rβ/γ activity, IL-2 β/γ was created by permanently attaching a small methoxy polyethylene glycol (mPEG) moiety in the IL-2Rα binding site. To improve pharmacokinetics, IL-2 β/γ was transiently attached to a 40 kDa mPEG carrier via a TransCon (transient conjugation) linker creating a prodrug, TransCon IL-2 β/γ, with sustained release of IL-2 β/γ. IL-2 β/γ was characterized in binding and primary cell assays while TransCon IL-2 β/γ was studied in tumor-bearing mice and cynomolgus monkeys. IL-2 β/γ demonstrated selective and potent human IL-2Rβ/γ binding and activation without IL-2Rα interactions. TransCon IL-2 β/γ showed slow-release pharmacokinetics with a low C TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2. It has remarkable and durable pharmacodynamic effects in monkeys and potential for improved clinical efficacy and tolerability compared with aldesleukin. TransCon IL-2 β/γ is currently being evaluated in a Phase 1/2 clinical trial (NCT05081609).
Sections du résumé
BACKGROUND
Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ
METHODS
TransCon IL-2 β/γ was designed to optimally address these drawbacks. To abolish IL-2Rα binding yet retain strong IL-2Rβ/γ activity, IL-2 β/γ was created by permanently attaching a small methoxy polyethylene glycol (mPEG) moiety in the IL-2Rα binding site. To improve pharmacokinetics, IL-2 β/γ was transiently attached to a 40 kDa mPEG carrier via a TransCon (transient conjugation) linker creating a prodrug, TransCon IL-2 β/γ, with sustained release of IL-2 β/γ. IL-2 β/γ was characterized in binding and primary cell assays while TransCon IL-2 β/γ was studied in tumor-bearing mice and cynomolgus monkeys.
RESULTS
IL-2 β/γ demonstrated selective and potent human IL-2Rβ/γ binding and activation without IL-2Rα interactions. TransCon IL-2 β/γ showed slow-release pharmacokinetics with a low C
SUMMARY
TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2. It has remarkable and durable pharmacodynamic effects in monkeys and potential for improved clinical efficacy and tolerability compared with aldesleukin. TransCon IL-2 β/γ is currently being evaluated in a Phase 1/2 clinical trial (NCT05081609).
Identifiants
pubmed: 35817480
pii: jitc-2022-004991
doi: 10.1136/jitc-2022-004991
pmc: PMC9274542
pii:
doi:
Substances chimiques
Delayed-Action Preparations
0
Interleukin-2
0
Interleukin-2 Receptor alpha Subunit
0
Prodrugs
0
Banques de données
ClinicalTrials.gov
['NCT05081609']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors are or were employees and/or stockholders of Ascendis Pharma and declare competing financial interests.
Références
Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90
pubmed: 25200249
Clin Cancer Res. 2016 Feb 1;22(3):680-90
pubmed: 26832745
Cancer Res. 1990 Apr 1;50(7):2009-17
pubmed: 2317789
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11906-11
pubmed: 20547866
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
J Immunol. 1995 Feb 1;154(3):998-1006
pubmed: 7529807
Nat Rev Drug Discov. 2020 Mar;19(3):169-184
pubmed: 31492944
PLoS One. 2017 Jul 5;12(7):e0179431
pubmed: 28678791
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Eur J Pharm Sci. 2021 Oct 1;165:105928
pubmed: 34265405
Nat Commun. 2014 Nov 19;5:5479
pubmed: 25407222
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93
pubmed: 16477002
J Pharmacol Exp Ther. 2021 Nov;379(2):203-210
pubmed: 34362793
Mol Pharmacol. 2005 Nov;68(5):1439-54
pubmed: 16099846
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
J Immunol. 2013 Jun 15;190(12):6230-8
pubmed: 23677467
Exp Mol Med. 2021 Mar;53(3):318-327
pubmed: 33707742
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35058325
Blood. 1991 Sep 15;78(6):1538-44
pubmed: 1884020
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32317293
J Interferon Cytokine Res. 2018 Feb;38(2):45-68
pubmed: 29443657
Nat Commun. 2021 Aug 9;12(1):4785
pubmed: 34373459
J Clin Invest. 1991 Sep;88(3):825-32
pubmed: 1885772
BMC Genomics. 2020 Jan 2;21(1):2
pubmed: 31898484
Cancer Immunol Res. 2022 May 3;10(5):581-596
pubmed: 35286392
Endocr Connect. 2017 Nov;6(8):R171-R181
pubmed: 28947559
J Clin Invest. 2014 Jan;124(1):99-110
pubmed: 24292706
Blood. 2014 Dec 4;124(24):3572-6
pubmed: 25323825
Oncoimmunology. 2017 Jan 11;6(3):e1277306
pubmed: 28405498